117:
108:
330:
36:
453:) to jointly develop a drug for hemophilia B, a long-lasting recombinant factor IX Fc fusion protein candidate, rFIXFc. This partnership was extended the following year to also include the development of a long-lasting recombinant factor VIII Fc fusion protein candidate, rFVIIIFc, for the treatment of hemophilia A.
449:, and marketing of specialty pharmaceuticals (ReFacto, Mimpara and Kineret®) was initiated in the Nordic region. In 2005, the research and development portfolio was expanded through the acquisition of Arexis, a Swedish biotech company, and the following year a partnership was formed with Syntonix (subsequently
510:
Sobi is an international specialty healthcare company dedicated to rare diseases with a focus on treatments in haematology, immunology and speciality care. In 2013, Sobi had total revenues of SEK 2.2 billion (€253 M) and about 550 employees; by 2020 the revenue was SEK 15.261 billion and there were
479:
projects as well as
Kiobrina into phase III were taken. The following year the first patient was enrolled in the phase 3 study for Kiobrina and data from the rFVIIIFc hemophilia phase I/II study were presented showing an approximately 1.7-fold increase in half-life compared with Advate. The company
463:
took the decision to enter final registration studies for the recombinant factor FIXFc. The company also received positive data regarding its
Kiobrina phase II program, an investigational enzyme replacement therapy to improve growth in preterm infants who receive pasteurized breast milk or infant
819:
407:
Sobi has been involved in the process development and manufacturing of recombinant protein drugs since the technology was first developed around 30 years ago, then as part of
888:
826:
893:
878:
69:
394:
456:
In 2008, an agreement with Amgen regarding the acquisition of the products
Kepivance and Stemgen as well as a global license for Kineret was signed
383:
736:
883:
487:
for ReFacto/Xyntha was extended until 2020 in addition to the agreement to return the co-promotion rights for the Nordic region for ReFacto to
898:
649:
873:
347:
772:
903:
498:
Guido
Oelkers was appointed President and CEO in May 2017, succeeding Geoffrey McDonough. Oelkers had previously been CEO of
382:
Sobi traces its origins to a subsidiary of Kärnbolaget
Aktiebolag Biokemisk Industri in the 1930s, which changed its name to
794:
564:
430:, a process development unit for protein drugs and a plasma product operation. In 2002 Sobi sold its plasma operation to
46:
572:
560:
217:
369:
87:
536:
55:
351:
707:
748:
552:
495:
initiated global pediatric clinical trials of their long-lasting hemophilia A and B product candidates.
516:
145:
17:
583:. The company also market a portfolio of specialty and rare disease products for partner companies.
65:
61:
656:
623:
340:
182:
51:
475:, and Swedish Orphan Biovitrum AB (publ) was formed. In addition, the decisions to advance both
155:
540:
544:
563:, and the 2020 annual report shows a further six products as "pre-market" in the areas of
8:
434:
as part of efforts to concentrate operations on protein-based and small molecular drugs.
427:
298:
116:
681:
241:
107:
423:
262:
127:
867:
512:
141:
135:
472:
437:
In 2004, Biovitrum started to manufacture the active protein component for
568:
528:
492:
460:
450:
302:
267:
476:
446:
431:
408:
354: in this section. Unsourced material may be challenged and removed.
306:
426:
and MPM Capital Funds. Operations included a research unit focused on
468:
415:
399:
310:
203:
Treatments in the areas of haematology, immunology and specialty care
165:
414:
Biovitrum was formed in 2001 through the merger of several units of
329:
316:
In 2020 it had a revenue of SEK 15.261 billion and 1,509 employees.
35:
556:
532:
524:
189:
715:
548:
491:
for a payment of USD 47.4 M. The same year, the Sobi and partner
388:
520:
499:
488:
484:
471:
acquired
Swedish Orphan International Holding AB, a pioneer in
442:
419:
438:
229:
580:
856:
799:
576:
445:’s) ReFacto® and ReFacto/Xyntha® drugs for treatment of
278:
773:"Guido Oelkers appointed President and CEO at Sobi"
737:
Change of company name for
Biovitrum AB, 2010-06-21
422:) and spun off to a consortium of investors led by
820:"Report for the fourth quarter and year-end 2013"
865:
301:company dedicated to treatments in the areas of
50:, potentially preventing the article from being
889:Pharmaceutical companies established in 2001
644:
642:
640:
638:
636:
586:
894:Manufacturing companies based in Stockholm
879:Companies related to the Wallenberg family
115:
106:
70:reliable, independent, third-party sources
812:
633:
370:Learn how and when to remove this message
88:Learn how and when to remove this message
674:
618:
616:
614:
612:
610:
608:
606:
511:1,509 employees. The share is listed at
64:by replacing them with more appropriate
650:"Annual and Sustainability Report 2020"
624:"Annual and sustainability report 2022"
47:too closely associated with the subject
14:
866:
787:
700:
884:Swedish companies established in 2001
603:
899:Companies listed on Nasdaq Stockholm
765:
352:adding citations to reliable sources
323:
29:
404:to become KabiVitrum in the 1970s.
24:
874:Pharmaceutical companies of Sweden
483:In 2012 the supply agreement with
480:also established a US subsidiary.
25:
915:
848:
749:"Spago Nanomedical AB (SPAGO-SS)"
519:. The company's products include
328:
45:may rely excessively on sources
34:
339:needs additional citations for
286:Footnotes / references
741:
730:
27:Swedish pharmaceutical company
13:
1:
904:2006 initial public offerings
682:"Swedish Orphan Biovitrum AB"
596:
575:, acute graft failure (aGF),
309:and specialty care, based in
7:
591:Synagis (From Astrazeneca)
295:Swedish Orphan Biovitrum AB
101:Swedish Orphan Biovitrum AB
10:
920:
505:
459:In 2009, Sobi and partner
319:
587:Acquisitions and licenses
284:
274:
261:
251:
239:
227:
215:
207:
199:
172:
161:
151:
133:
123:
114:
105:
393:in 1951 and merged with
579:and chronic refractory
547:for several disorders;
825:. Sobi. Archived from
655:. Sobi. Archived from
593:Dova Pharmaceuticals
527:for the treatment of
795:"SOBI: Business Man"
348:improve this article
297:is an international
832:on 30 November 2014
253:Number of employees
102:
775:. Sobi. 4 May 2017
428:metabolic diseases
247:SEK 26.5 bn (2022)
235:SEK 52.5 bn (2022)
223:SEK 14.4 bn (2022)
211:SEK 18.8 bn (2022)
188:Bo Jesper Hansen (
100:
686:www.bloomberg.com
380:
379:
372:
299:biopharmaceutical
292:
291:
98:
97:
90:
16:(Redirected from
911:
860:
859:
857:Official website
842:
841:
839:
837:
831:
824:
816:
810:
809:
807:
805:
791:
785:
784:
782:
780:
769:
763:
762:
760:
759:
745:
739:
734:
728:
727:
725:
723:
714:. Archived from
704:
698:
697:
695:
693:
678:
672:
671:
669:
667:
661:
654:
646:
631:
630:
628:
620:
513:Nasdaq Stockholm
403:
392:
375:
368:
364:
361:
355:
332:
324:
244:
232:
218:Operating income
142:Nasdaq Stockholm
119:
110:
103:
99:
93:
86:
82:
79:
73:
38:
30:
21:
919:
918:
914:
913:
912:
910:
909:
908:
864:
863:
855:
854:
851:
846:
845:
835:
833:
829:
822:
818:
817:
813:
803:
801:
793:
792:
788:
778:
776:
771:
770:
766:
757:
755:
747:
746:
742:
735:
731:
721:
719:
706:
705:
701:
691:
689:
680:
679:
675:
665:
663:
659:
652:
648:
647:
634:
629:. June 1, 2023.
626:
622:
621:
604:
599:
592:
589:
508:
397:
386:
376:
365:
359:
356:
345:
333:
322:
288:
254:
240:
228:
220:
195:
181:Guido Oelkers (
175:
138:
94:
83:
77:
74:
59:
39:
28:
23:
22:
15:
12:
11:
5:
917:
907:
906:
901:
896:
891:
886:
881:
876:
862:
861:
850:
849:External links
847:
844:
843:
811:
786:
764:
740:
729:
718:on 25 May 2021
699:
673:
662:on 25 May 2021
632:
601:
600:
598:
595:
588:
585:
507:
504:
424:Nordic Capital
378:
377:
336:
334:
327:
321:
318:
290:
289:
282:
281:
276:
272:
271:
265:
259:
258:
255:
252:
249:
248:
245:
237:
236:
233:
225:
224:
221:
216:
213:
212:
209:
205:
204:
201:
197:
196:
194:
193:
186:
178:
176:
173:
170:
169:
163:
159:
158:
156:Pharmaceutical
153:
149:
148:
139:
134:
131:
130:
125:
121:
120:
112:
111:
96:
95:
42:
40:
33:
26:
9:
6:
4:
3:
2:
916:
905:
902:
900:
897:
895:
892:
890:
887:
885:
882:
880:
877:
875:
872:
871:
869:
858:
853:
852:
828:
821:
815:
800:
796:
790:
774:
768:
754:
750:
744:
738:
733:
717:
713:
709:
703:
687:
683:
677:
658:
651:
645:
643:
641:
639:
637:
625:
619:
617:
615:
613:
611:
609:
607:
602:
594:
584:
582:
578:
574:
570:
566:
562:
558:
554:
550:
546:
542:
538:
534:
530:
526:
522:
518:
514:
503:
501:
496:
494:
490:
486:
481:
478:
474:
470:
465:
462:
457:
454:
452:
448:
444:
440:
435:
433:
429:
425:
421:
417:
412:
410:
405:
401:
396:
390:
385:
374:
371:
363:
353:
349:
343:
342:
337:This section
335:
331:
326:
325:
317:
314:
312:
308:
304:
300:
296:
287:
283:
280:
277:
273:
269:
266:
264:
260:
256:
250:
246:
243:
238:
234:
231:
226:
222:
219:
214:
210:
206:
202:
198:
191:
187:
184:
180:
179:
177:
171:
167:
164:
160:
157:
154:
150:
147:
143:
140:
137:
132:
129:
126:
122:
118:
113:
109:
104:
92:
89:
81:
71:
67:
63:
57:
53:
49:
48:
43:This article
41:
37:
32:
31:
19:
834:. Retrieved
827:the original
814:
802:. Retrieved
798:
789:
777:. Retrieved
767:
756:. Retrieved
752:
743:
732:
720:. Retrieved
716:the original
711:
702:
690:. Retrieved
685:
676:
664:. Retrieved
657:the original
590:
509:
497:
482:
473:orphan drugs
466:
458:
455:
436:
413:
406:
381:
366:
357:
346:Please help
341:verification
338:
315:
294:
293:
285:
257:1,600 (2022)
242:Total equity
230:Total assets
162:Headquarters
124:Company type
84:
75:
60:Please help
44:
688:. Bloomberg
569:haemophilia
529:haemophilia
500:BSN Medical
493:Biogen Idec
461:Biogen Idec
451:Biogen Idec
398: [
387: [
303:haematology
268:Investor AB
868:Categories
758:2022-09-14
597:References
477:hemophilia
447:hemophilia
432:Octapharma
409:KabiVitrum
313:, Sweden.
307:immunology
174:Key people
62:improve it
52:verifiable
708:"History"
469:Biovitrum
467:In 2010,
464:formula.
416:Pharmacia
311:Stockholm
166:Stockholm
136:Traded as
66:citations
18:Biovitrum
753:biotickr
557:Gamifant
533:Doptelet
525:Alprolix
441:’s (now
360:May 2020
279:sobi.com
200:Products
190:chairman
168:, Sweden
152:Industry
78:May 2020
549:Synagis
545:Kineret
515::
506:Company
320:History
275:Website
270:(34.7%)
208:Revenue
144::
56:neutral
836:25 May
722:25 May
666:25 May
521:Elocta
489:Pfizer
485:Pfizer
443:Pfizer
420:Pfizer
395:Vitrum
263:Parent
128:Public
830:(PDF)
823:(PDF)
804:6 May
779:6 May
692:7 May
660:(PDF)
653:(PDF)
627:(PDF)
439:Wyeth
418:(now
402:]
391:]
838:2021
806:2020
781:2020
724:2021
712:Sobi
694:2020
668:2021
581:gout
573:sHLH
561:pHLH
559:for
555:and
551:for
539:and
535:for
523:and
517:SOBI
384:Kabi
146:SOBI
54:and
577:ALS
565:PNH
553:RSV
543:;
541:CLD
537:ITP
350:by
183:CEO
68:to
870::
797:.
751:.
710:.
684:.
635:^
605:^
571:,
567:,
531:;
502:.
411:.
400:sv
389:sv
305:,
840:.
808:.
783:.
761:.
726:.
696:.
670:.
373:)
367:(
362:)
358:(
344:.
192:)
185:)
91:)
85:(
80:)
76:(
72:.
58:.
20:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
